美股市場個股詳情

SUPN Supernus Pharmaceuticals

添加自選

30.420
-0.410-1.33%

收盤價 05/06 16:00 (美東)

30.420
0.0000.00%

盤後 16:09 (美東)

16.72億總市值1521.00市盈率TTM

Supernus Pharmaceuticals股票討論區

登錄發表評論

Moomoo AI

01/26 20:21

Supernus Pharmaceuticals' high P/E ratio is sustained by expectations of robust future growth, surpassing market average. Investors' belief in insignificant earnings deterioration risk bolsters the share price.

The Price Is Right For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Moomoo AI

2023/11/04 00:16

Caution is raised with substantial selling of Supernus Pharmaceuticals stock by key insiders and lack of buying in the past year. Insider ownership isn't high, indicating alignment with other shareholders. Evaluate carefully before purchasing due to these factors.

Supernus Pharmaceuticals Repeat Insider Selling Not A Positive Indicator

逍遥投资派

2023/05/26 23:15

$Supernus Pharmaceuticals(SUPN.US)$5年來營收除2019年外增長了4年，平均增速17%，營業利潤反而在增長3年後，2021年大幅下滑54.7%，2022年繼續大幅下滑42.6%，主要是由營業費用暴增引起的。
查了一下資產負債表，果然2021年商譽從4.42億增加到9.02億，這次收購使公司的運營效率大幅下滑，至今未緩過來。
2023Q1營收增長0.8%，營業利潤在非常低的基數上增長了34%達到353萬，淨利潤則由於利息收入的大幅下滑而萎縮了34%。
目前市盈率32.2，市盈率TTM 37.2，在運營效率改善前缺乏投資價值。

已翻譯

Bertramie

2021/10/12 15:33

$Supernus Pharmaceuticals(SUPN.US)$
Supernus Pharmaceuticals agreed to acquire Adamas Pharmaceuticals for $8.10 a share in cash, or about $400 million, for two drugs approved for use in patients with Parkinson's disease. The transaction also includes two contingent value rights (CVR) with a total value of $1 per share in cash, or approximately $50 million. The initial cash consideration represents a premium of about 75% to Adamas' Oct. 8 closing share price.

暫無評論

分析

分析師評級

暫無數據

目標價預測

暫無數據

熱議

美股

綜合熱度